-
Mashup Score: 1How JAK Inhibitors Revolutionized Dermatology Care - 2 year(s) ago
Dr. Brett King returns to discuss the impact of JAK inhibitors in the management of atopic dermatitis.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0How JAK Inhibitors Revolutionized Dermatology Care - 2 year(s) ago
Dr. Brett King returns to discuss the impact of JAK inhibitors in the management of atopic dermatitis.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
The new #DermDiscussions is here! Dr. Brett King returns to discuss the impact of #JAK inhibitors in the management of #atopicdermatitis. #dermtwitter https://t.co/EBAXNcxvbA
-
-
Mashup Score: 0
In this episode of Derm Discussions, vitiligo expert John Harris, MD, PhD, discusses new tactics and therapeutic options in treating inflammatory skin disorders like vitiligo, alopecia areata, and atopic dermatitis.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
ICYMI: Vitiligo expert John Harris, MD, PhD, discusses new tactics and therapeutic options in treating inflammatory skin disorders like #vitiligo, #alopeciaareata, and #atopicdermatitis in the newest episode of #DermDiscussions https://t.co/HQ40PxjUxs
-
-
Mashup Score: 0JAK Inhibitors: Looking at Selectivity and Safety - 3 year(s) ago
Brett King, MD, PhD, encourages dermatologists to wait for more clinical data before making any assumptions on the drug class’ safety and selectivity.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
On the latest #DermDiscussions with @BradMPH, Brett King, MD, PhD, talked about the black box warning of #tofacitinib, suggesting it may not be a cause for concern yet for dermatology until all clinical data of the JAKs are analyzed and summarized. https://t.co/TeWhjLhfgG
-
-
Mashup Score: 0JAK Inhibitors: Looking at Selectivity and Safety - 3 year(s) ago
Brett King, MD, PhD, encourages dermatologists to wait for more clinical data before making any assumptions on the drug class’ safety and selectivity.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
“We need to understand what the entirety of the data says to know how to think about using [JAKs] in any patient population,” says Brett King, MD, PhD, of @YaleMed. #DermDiscussions https://t.co/TeWhjKZEp8
-
-
Mashup Score: 0JAK Inhibitors: Looking at Selectivity and Safety - 3 year(s) ago
Brett King, MD, PhD, encourages dermatologists to wait for more clinical data before making any assumptions on the drug class’ safety and selectivity.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
From #DermDiscussions: Brett King, MD, PhD, discusses the safety of JAK inhibitors and what dermatologists should know about the drug class. https://t.co/TeWhjLhfgG
-
-
Mashup Score: 0New Frontiers in Dermatology: Defining the JAK-STAT Pathway - 3 year(s) ago
Brett King, MD, PhD, provides an overview of JAK inhibitors and their interaction with the JAK-STAT pathway.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
From #DermDiscussions: “We are not targeting a #cytokine, but we are also not knocking down all T-cells like with cyclosporine. These are sort-of non-targeted targeted therapies.” https://t.co/bcGlkl9iJf
-
-
Mashup Score: 0New Frontiers in Dermatology: Defining the JAK-STAT Pathway - 3 year(s) ago
Brett King, MD, PhD, provides an overview of JAK inhibitors and their interaction with the JAK-STAT pathway.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
What is the JAK-STAT pathway, and how does it relate to #dermatologic disease? Brett King, MD, PhD, explains. #DermDiscussions https://t.co/bcGlklqU7P
-
-
Mashup Score: 0New Frontiers in Dermatology: Defining the JAK-STAT Pathway - 3 year(s) ago
Brett King, MD, PhD, provides an overview of JAK inhibitors and their interaction with the JAK-STAT pathway.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
From #DermDiscussions with @BradMph: Brett King, MD, PhD, Associate Professor of Dermatology at @YaleMed, gives a brief overview of the JAK-STAT pathway. https://t.co/bcGlkl9iJf
-
-
Mashup Score: 0Brett King, MD, PhD: The Promise of Janus Kinase Inhibitors - 3 year(s) ago
On the latest Derm Discussions, Brett King, MD, PhD, joins Brad Glick, DO, to discuss the potential of the JAK inhibitor class for dermatology.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
#ICYMI: @BradMph and Brett King, MD, PhD, discuss janus kinase inhibitors and what they could mean for dermatology. #DermDiscussions https://t.co/2EbIo0Ojac https://t.co/BjGaVl6oJk
-
"Just as dupilumab was revolutionary to AD, so will be the JAK inhibitors.” - Dr. Brett King of @YaleMedicine #dermtwitter #atopicdermatitis #dermpodcast Hear more from the latest #DermDiscussions at the link: https://t.co/Vcz9zB3o7e